William Blair
http://www.williamblair.comWilliam Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, it has been committed to helping clients achieve their financial objectives.
View Older Stories View More Recent Stories
-
William Blair Shuffles Analyst Conviction List for April 2026
-
William Blair on nCino Inc. (NCNO): 'AI May Disrupt Pockets of SaaS—but the Playbook Is Different in Banking'
-
William Blair on Biogen (BIIB): 'we see potential to add $1.54 billion in sales' through APLS deal
-
William Blair on Marvell (MRVL): Nvidia partnership, investment 'should help quell' questions of IP quality
-
William Blair on Aehr Test Systems (AEHR): new order estimated at $10m, 'confirmatory of our thesis'
-
William Blair Downgrades Apellis Pharmaceuticals (APLS) to Market Perform
-
William Blair Starts MiniMed Group (MMED) at Outperform
-
William Blair Upgrades 10X Genomics (TXG) to Outperform
-
Form 497K WILLIAM BLAIR FUNDS
-
Form 497 WILLIAM BLAIR FUNDS
-
William Blair on Incyte (INCY): 'encouraged' by Ph3 data and deepened responses
-
William Blair: 'we view BridgeBio as a core smidcap biotech holding'
-
William Blair on Autolus Therapeutics plc (AUTL): LT blockbuster oppty despite YTD stock decline
-
William Blair on Sterling Construction (STRL): shares outperforming on Meta El Paso data center news
-
William Blair on ARS Pharmaceuticals Inc (SPRY): FDA label update 'viewed positively'
-
William Blair on Kura Sushi USA Inc. (KRUS): 'expect a solid re-inflection into positive comps'
-
William Blair Starts Nlight (LASR) at Outperform
-
William Blair Reiterates Market Perform Rating on Enerpac Tool Group (EPAC) despite service biz weakness
-
Wolfspeed completes $475.9 million refinancing with convertible notes
-
Strategic Refinancing and New Equity Issuance Support Wolfspeed’s Long-term Growth Potential
-
William Blair stays Outperform on AAR Corporation (AIR): sees 20% upside in next 12 months
-
William Blair on Cintas (CTAS): expected to continue 'strong earnings growth'
-
William Blair stays Outperform on Viking Therapeutic (VKTX) amid 'torrid pace' in advancing VK2735
-
William Blair on Dianthus Therapeutics (DNTH): FDA removing ANA criteria 'an incremental positive'
-
Secondary Market Hits Record $220 Billion in 2025
-
William Blair Reiterates Outperform Rating on MillerKnoll (MLKN) amid post-earnings selloff
-
William Blair stays Outperform on Cardiff Oncology (CRDF) despite adoption hurdles, dilution risks
-
William Blair stays Outperform rated on Karman Holdings Inc (KRMN) after solid earnings, guidance raise
-
Adobe downgraded at William Blair on intensifying competitive pressure
-
William Blair Downgrades Adobe (ADBE) to Market Perform
-
William Blair stays Outperform on Ionis Pharmaceuticals (IONS); pricing update 'positive'
-
William Blair stays Market Perform on WillScot Holdings Corp (WSC) amid soft Feb. dodge starts
-
William Blair stays Outperform on Beam Therapeutics Inc (BEAM) after "decisive validation' of BEAM-302 profile
-
Generac stock tumbles as data center deal hopes disappoint
-
William Blair on Arm Holdings (ARM): new CPU product to pressure margins, but increases earnings power
-
William Blair Reiterates Outperform Rating on Circle Internet Group (CRCL)
-
William Blair stays Outperform on Vertical Aerospace Ltd. (EVTL) despite $110 million funding gap
-
William Blair on Watsco (WSO): selloff 'an overreaction' to HD's Mingledorff's acquisition
-
William Blair on Neurogene (NGNE): dosing update further de-risks NGN-401 profile
-
William Blair maintains Outperform rated on Cabaletta Bio Inc. (CABA) amid trial progress
-
Defense firm AEVEX files for NYSE IPO
-
William Blair on Pyxis Oncology Inc. (PYXS): 'encouraged' by enrollment pace of dose-expansion study
-
William Blair on Tarsus Pharmaceuticals (TARS): 'benefits from the large and motivated patient population'
-
William Blair on MaxCyte Inc. (MXCT): CFO appointment 'not all that needle-moving'
-
William Blair on Insmed (INSM): 'data overall supports approval'
-
William Blair Downgrades Avepoint Inc. (AVPT) to Market Perform
-
William Blair Downgrades Dropbox (DBX) to Underperform
-
William Blair Double Downgrades GitLab Inc (GTLB) to Underperform
-
William Blair on GoDaddy Inc (GDDY): 'we are optimistic'
-
William Blair Starts Eupraxia Pharmaceuticals (EPRX) at Outperform

